AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23703722 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total calcium intake (per 500 mg increase)
Number of subjects: 9033
Study 23703722 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D intake
Number of subjects: 9033
Study 23864987 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-based asthma care service via telephone
Number of subjects: 98
Study 23864987 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 98
Study 19029962 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 6
Study 19029962 — intervention group
Group type: COMPARATOR
Intervention: Control (non-rituximab-treated patients)
Number of subjects: 6
Study 17221265 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SSEP/MEP monitoring
Number of subjects: 100
Study 17221265 — intervention group
Group type: COMPARATOR
Intervention: MEP monitoring
Number of subjects: 100
Study 15174791 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered infusions via a central catheter
Number of subjects: 88
Study 15174791 — intervention group
Group type: COMPARATOR
Intervention: Non-filtered infusions via a central catheter
Number of subjects: 88
Study 11423928 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt with 10(8) bacteria/ml
Number of subjects: 24
Study 11423928 — intervention group
Group type: EXPERIMENTAL
Intervention: Products with reduced population of live flora (10(6) and 10(5) bacteria/ml)
Number of subjects: 24
Study 11423928 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 24
Study 11423928 — intervention group
Group type: COMPARATOR
Intervention: Heat-treated yoghurt (<15 bacteria/ml)
Number of subjects: 24
Study 9425382 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily amikacin (15 mg/kg, n = 27)
Number of subjects: 54
Study 9425382 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily amikacin (7.5 mg/kg, n = 27)
Number of subjects: 54
Study 8381943 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin and prednisolone (group Cy)
Number of subjects: 30
Study 8381943 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and prednisolone (group Az)
Number of subjects: 30
Study 2893638 — intervention group
Group type: EXPERIMENTAL
Intervention: Temelastine (100 mg, oral, twice daily for 7 days)
Number of subjects: 10
Study 2893638 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral, twice daily for 7 days)
Number of subjects: 10
Study 2910421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; triple-drug chemoprophylaxis of the CNS using methotrexate, hydrocortisone, and cytosine arabinoside.
Number of subjects: 430
Study 2910421 — intervention group
Group type: COMPARATOR
Intervention: Cranial irradiation and intrathecal methotrexate.
Number of subjects: 430
Study 2910421 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification period with Cytoxan (cyclophosphamide) and asparaginase after induction; triple-drug chemoprophylaxis of the CNS.
Number of subjects: 430
Study 31393402 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate at 2 grams/hour
Number of subjects: 62
Study 31393402 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate at 1 gram/hour
Number of subjects: 62
Study 28944527 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure mirror exposure (n=17)
Number of subjects: 35
Study 28944527 — intervention group
Group type: COMPARATOR
Intervention: Guided mirror exposure (n=18)
Number of subjects: 35
Study 24652221 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 for 2 months followed by folic acid for 2 months
Number of subjects: 74
Study 24652221 — intervention group
Group type: COMPARATOR
Intervention: Folic acid for 2 months
Number of subjects: 74
Study 24652221 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusive dialysis
Number of subjects: 74
Study 24652221 — intervention group
Group type: EXPERIMENTAL
Intervention: Convective dialysis
Number of subjects: 74
Study 24135139 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acids (EAAs) 20 g twice daily for 1 week before and 2 weeks after TKA
Number of subjects: 28
Study 21670770 — intervention group
Group type: EXPERIMENTAL
Intervention: APC combined with high dose rate (HDR) brachytherapy
Number of subjects: 93
Study 21670770 — intervention group
Group type: EXPERIMENTAL
Intervention: APC combined with photodynamic therapy (PDT)
Number of subjects: 93
Study 21670770 — intervention group
Group type: COMPARATOR
Intervention: APC alone
Number of subjects: 93
Study 21670770 — intervention group
Group type: EXPERIMENTAL
Intervention: APC combined with HDR
Number of subjects: 93
Study 21670770 — intervention group
Group type: EXPERIMENTAL
Intervention: APC combined with PDT
Number of subjects: 93
Study 21670770 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 19494744 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive pedicle screw placement
Number of subjects: 30
Study 19494744 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval pedicle screw placement
Number of subjects: 30
Study 16756732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 16756732 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 50
Study 15118522 — intervention group
Group type: COMPARATOR
Intervention: Placebo group from the PROWESS trial
Number of subjects: 840
Study 15118522 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C levels
Number of subjects: 840
Study 15118522 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6 levels
Number of subjects: 840
Study 11026657 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/wk for 3 months
Number of subjects: 40
Study 11026657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9301397 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 60
Study 9301397 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 60
Study 9301397 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 60
Study 8112439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terfenadine (180 mg q.d., for three days)
Number of subjects: 6
Study 8112439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3013967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 0
Study 3013967 — intervention group
Group type: COMPARATOR
Intervention: 25-hydroxyvitamin D3 (25-OHD3)
Number of subjects: 0
Study 31735180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 92
Study 31735180 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 92
Study 28609505 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allografts (ADMs) with coronally advanced flaps
Number of subjects: 0
Study 26017871 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg once a day for 30 days
Number of subjects: 16
Study 26017871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23104710 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (Sapylin) applied to the axillary fossa plus placement of closed suction drainage
Number of subjects: 111
Study 23104710 — intervention group
Group type: COMPARATOR
Intervention: Control group with placement of closed suction drainage only
Number of subjects: 111
Study 21969505 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional and new prognostic factors evaluated (including FISH, IGHV mutation status, ZAP‐70 expression)
Number of subjects: 930
Study 17955230 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9*2 or CYP2C9*3
Number of subjects: 103
Study 17955230 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9*3
Number of subjects: 103
Study 17955230 — intervention group
Group type: COMPARATOR
Intervention: CYP2C9*1*1
Number of subjects: 103
Study 17145679 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (lavender, chamomile, rosemary, lemon), 20 min sessions, 3 times per week for two 3-week periods with a 1-week break
Number of subjects: 36
Study 17145679 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aromatherapy massage)
Number of subjects: 36
Study 14665499 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly efficacious treatment (n = 257)
Number of subjects: 2971
Study 14665499 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately efficacious treatment (n = 965)
Number of subjects: 2971
Study 14665499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildly efficacious treatment (n = 891)
Number of subjects: 2971
Study 10365809 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose ursodeoxycholic acid (13-15 mg x kg(‐1) x day(‐1))
Number of subjects: 155
Study 10365809 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (23-25 mg x kg(‐1) x day(‐1))
Number of subjects: 155
Study 10365809 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ursodeoxycholic acid (5-7 mg x kg(‐1) x day(‐1))
Number of subjects: 155
Study 10365809 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of ursodeoxycholic acid
Number of subjects: 155
Study 7729434 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting programme 5 days each week for 3 years (W-group)
Number of subjects: 26
Study 7729434 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting programme for 3 years with additional running programme (2 miles of jogging once a week during the 3rd year) (R1-group)
Number of subjects: 26
Study 7729434 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting programme during the 1st year and combined jogging and weight lifting programme during the 2nd and 3rd years (R2-group)
Number of subjects: 26
Study 7729434 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (W, R1, R2)
Number of subjects: 26
Study 1646292 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin, etoposide (VP‐16) + methylglyoxal bisguanylhydrazone (MGBG; PVp)
Number of subjects: 680
Study 1646292 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin, etoposide (VP‐16) + methylglyoxal bisguanylhydrazone (MGBG; PVpM)
Number of subjects: 680
Study 1646292 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin, vinblastine (PVe)
Number of subjects: 680
Study 1646292 — intervention group
Group type: EXPERIMENTAL
Intervention: PVe alternating with vinblastine, mitomycin (PVeMi)
Number of subjects: 680
Study 1646292 — intervention group
Group type: EXPERIMENTAL
Intervention: fluorouracil, vincristine, mitomycin/cyclophosphamide, doxorubicin, cisplatin (FOMi/CAP)
Number of subjects: 680
Study 7104156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg daily)
Number of subjects: 10
Study 7104156 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 10
Study 7104156 — intervention group
Group type: COMPARATOR
Intervention: Control values
Number of subjects: 10
Study 31956914 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sleep duration
Number of subjects: 3144
Study 31956914 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer sleep duration (using Mendelian randomization)
Number of subjects: 3144
Study 30206091 — intervention group
Group type: EXPERIMENTAL
Intervention: Legally styled consent form with 55 risks identified in the world literature
Number of subjects: 220
Study 30206091 — intervention group
Group type: COMPARATOR
Intervention: Medically styled consent form with 13 serious or most common risks
Number of subjects: 220
Study 30206091 — intervention group
Group type: EXPERIMENTAL
Intervention: Legally styled consent form
Number of subjects: 220
Study 30206091 — intervention group
Group type: COMPARATOR
Intervention: Medically styled consent form
Number of subjects: 220
Study 26660707 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating norfloxacin and rifaximin
Number of subjects: 334
Study 26660707 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin alone
Number of subjects: 334
Study 26660707 — intervention group
Group type: COMPARATOR
Intervention: Rifaximin alone
Number of subjects: 334
Study 26660707 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin and rifaximin
Number of subjects: 334
Study 23906550 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visit
Number of subjects: 459
Study 23906550 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior group meetings
Number of subjects: 459
Study 23906550 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 459
Study 22324772 — intervention group
Group type: EXPERIMENTAL
Intervention: LipiFlow® Thermal Pulsation System treatment
Number of subjects: 21
Study 21035609 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week couple therapy intervention (n=18)
Number of subjects: 35
Study 21035609 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (n=17)
Number of subjects: 35
Study 18727648 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful drug withdrawal
Number of subjects: 83
Study 18727648 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of migraine with more than eight headache days/month
Number of subjects: 83
Study 18727648 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher frequency of migraine after drug withdrawal
Number of subjects: 83
Study 18727648 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of previous preventive treatments
Number of subjects: 83
Study 16104447 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physical therapy (CPT) after thoracoscopic surgery
Number of subjects: 36
Study 16104447 — intervention group
Group type: COMPARATOR
Intervention: Chest physical therapy (CPT) after thoracotomy
Number of subjects: 36
Study 16104447 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic surgery
Number of subjects: 36
Study 16104447 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 36
Study 12215965 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol (500 I.U. daily)
Number of subjects: 9
Study 12215965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12215965 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive treadmill exercise
Number of subjects: 9
Study 9689556 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (150 IU/kg per dose, increasing to 300 IU/kg per dose, every 3 weeks for 6 months)
Number of subjects: 71
Study 9689556 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 71
Study 9689556 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 8107991 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DOTA
Number of subjects: 300
Study 8107991 — intervention group
Group type: COMPARATOR
Intervention: Gd-DTPA
Number of subjects: 300
Study 8107991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Gd-DOTA and Gd-DTPA
Number of subjects: 300
Study 2669665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex gum (4 mg), n = 92
Number of subjects: 182
Study 2669665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex gum (4 mg), n = 64 (daily users)
Number of subjects: 182
Study 2669665 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum, n = 69 (daily users)
Number of subjects: 182
Study 2669665 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex gum
Number of subjects: 182
Study 786820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (150 mg daily for the first week, increased to 225 mg in the second week)
Number of subjects: 73
Study 786820 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide (30 mg daily for the first week, increased to 45 mg in the second week)
Number of subjects: 73
Study 786820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 73
Study 786820 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 73
Study 30552176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutikizumab 200 mg subcutaneously every 2 weeks for 24 weeks
Number of subjects: 132
Study 30552176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 30552176 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutikizumab
Number of subjects: 132
Study 28579756 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Lipid (BL)
Number of subjects: 158
Study 28579756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 28579756 — intervention group
Group type: COMPARATOR
Intervention: Armolipid Plus® (AM)
Number of subjects: 158
Study 26469827 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (combination drug containing sacubitril and valsartan)
Number of subjects: 0
Study 26469827 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (angiotensin-converting enzyme inhibitor)
Number of subjects: 0
Study 23946212 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 203
Study 23946212 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine (DFO)
Number of subjects: 203
Study 23946212 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox with concomitant hydroxyurea
Number of subjects: 203
Study 21811939 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 22
Study 21811939 — intervention group
Group type: COMPARATOR
Intervention: High resolution endoscopy (HRE)
Number of subjects: 22
Study 19719452 — intervention group
Group type: EXPERIMENTAL
Intervention: Single vaccination with modified-live respiratory virus vaccine
Number of subjects: 612
Study 19719452 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination with modified-live respiratory virus vaccine
Number of subjects: 612
Study 19719452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine during finishing phase)
Number of subjects: 612
Study 16698351 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated TENS
Number of subjects: 148
Study 16698351 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 148
Study 16698351 — intervention group
Group type: COMPARATOR
Intervention: Control (no analgesics)
Number of subjects: 148
Study 15604849 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0
Study 15604849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 0
Study 15604849 — intervention group
Group type: COMPARATOR
Intervention: Nontoxic systemic drugs
Number of subjects: 0
Study 11309833 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange treatment administered every other day for 2 weeks
Number of subjects: 22
Study 11309833 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 22
Study 11309833 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover to active treatment after failing sham treatment
Number of subjects: 22
Study 11309833 — intervention group
Group type: COMPARATOR
Intervention: Crossover to sham treatment after failing active treatment
Number of subjects: 22
Study 9407564 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at concentrations of 1, 5, 10, and 20 parts per million (ppm)
Number of subjects: 11
Study 9407564 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 ppm NO)
Number of subjects: 11
Study 9407564 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 11
Study 7712700 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 75 g oral glucose tolerance test (OGTT)
Number of subjects: 1122
Study 2575550 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (SST)
Number of subjects: 220
Study 2575550 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 220
Study 2575550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 855911 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 350 microng
Number of subjects: 0
Study 855911 — intervention group
Group type: COMPARATOR
Intervention: POR 8 5.5 IU
Number of subjects: 0
Study 855911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study 31789899 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml of tea with milk
Number of subjects: 50
Study 31789899 — intervention group
Group type: COMPARATOR
Intervention: 250 ml of water
Number of subjects: 50
Study 31577341 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 267
Study 31577341 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 267
Study 31577341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 28677826 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab + lenalidomide/dexamethasone (ELd)
Number of subjects: 0
Study 28677826 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide/dexamethasone (Ld)
Number of subjects: 0
Study 25581661 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink-EtOH adjustments using transdermal alcohol sensor (TAS) readings and self-reported diaries.
Number of subjects: 220
Study 25581661 — intervention group
Group type: EXPERIMENTAL
Intervention: Drink-EtOH adjustment ratios (EtOH adjusted/unadjusted amounts).
Number of subjects: 220
Study 25581661 — intervention group
Group type: EXPERIMENTAL
Intervention: Degree of adjustment controlling for raw number of drinks and other covariates.
Number of subjects: 220
Study 25581661 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher correlations between adjusted versus raw drinks/event and TAS areas under the curve.
Number of subjects: 220
Study 21672300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 70
Study 21672300 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Training (RT)
Number of subjects: 70
Study 20587028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (n = 309)
Number of subjects: 612
Study 20587028 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 303)
Number of subjects: 612
Study 20587028 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive women (n = 72)
Number of subjects: 612